Developer docs
API playgroundTry for free, no card

Search company profiles

Bioeq

Full company profile

uuid000bkyf

Namestring
Bioeq
Legal namestring
Bioeq AG
Websiteurl
bioeq.ch
Company typeenum
Private
Founded yearstring
-
Descriptiontext

Bioeq AG is a Swiss biopharmaceutical joint venture, equally owned by Polpharma Biologics Group and Formycon AG, headquartered in Zug, Switzerland. The company develops, manufactures, licenses, and commercializes biosimilars globally, with a focused portfolio centered on Ranibizumab (FYB201), a monoclonal antibody biosimilar to Roche/Genentech's Lucentis. Ranibizumab targets vascular endothelial growth factor (VEGF) and is indicated for retinal disorders including age-related macular degeneration (AMD), choroidal neovascularization (CNV), retinal vein occlusion, and diabetic retinopathy. The same molecule is marketed under multiple brand names across jurisdictions: Cimerli (US, 2022 FDA approval as the first interchangeable Lucentis biosimilar), Ranivisio (European Commission and Swissmedic, launched commercially in Europe starting November 2025 with Teva), Ongavia (UK MHRA, 2022), NUFYMCO (US, 2025 FDA approval commercialized with Zydus Lifesciences), and BioUcenta (Africa via Bio Usawa).

Bioeq operates an asset-light, B2B licensing and royalty business model. The company itself is small (1-10 employees) and handles development, manufacturing oversight, and registration through its JV parents' capabilities, while out-licensing commercialization rights to established regional pharmaceutical partners in each territory. Key partners include Teva (Europe, Israel), Zydus Lifesciences (US), MS Pharma (Middle East/Africa), Bio Usawa Biotechnology (Rwanda/Africa), Actor Pharma (Australia), Megalabs (Latin America), and Horus Pharma (selected European countries). Pricing is set independently by each partner in its market and is not publicly disclosed by Bioeq. Its customers are therefore pharmaceutical licensees rather than end prescribers or patients, with end-user demand driven by ophthalmologists, hospitals, clinics, and patients seeking affordable alternatives to the high-cost originator Lucentis.

Short descriptiontext

Bioeq AG is a Swiss biopharmaceutical joint venture (Polpharma Biologics and Formycon) that develops, manufactures, and out-licenses the Ranibizumab biosimilar of Lucentis globally, serving ophthalmology patients with retinal disorders via regional pharmaceutical commercialization partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersZug, Switzerland
HQ citystring
Zug
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar development, biopharmaceutical licensing, monoclonal antibody biosimilars, ophthalmology therapeutics, biologic manufacturing
Industry4 codes
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAHAJ
Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biosimilars
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Biosimilar Licensing and Commercialization
TypeLicensing Royalties
Description

Bioeq develops biosimilars and out-licenses them to established pharmaceutical companies for commercialization in specific territories. Partners handle local registration, marketing, and distribution while Bioeq manages development, manufacturing, and supply.

bioeq.ch
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Supply Chain, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Bioeq AG is a Swiss biopharmaceutical joint venture that develops, manufactures, and out-licenses biosimilars of biopharmaceutical products globally. Its core offering is a Ranibizumab biosimilar (FYB201) to Lucentis, approved by FDA, EMA, Swissmedic, UK MHRA, and Brazil's ANVISA for retinal disorders including age-related macular degeneration, choroidal neovascularization, retinal vein occlusion, and diabetic retinopathy. The company licenses commercialization rights to established pharmaceutical partners in each territory rather than selling directly, focusing on development, manufacturing, registration, and supply.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • First Lucentis biosimilar launched in Europe and first interchangeable biosimilar approved by FDA
Product overview1 text field

Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG, focused on developing, producing, licensing, and commercializing biosimilars globally. The company's primary product is Ranibizumab, a biosimilar to Lucentis, which is marketed under multiple brand names across different markets: Cimerli (FDA-approved, US), Ranivisio (EC and Swissmedic-approved, Europe/Switzerland), and Ongavia (MHRA-approved, UK). In December 2025, Bioeq received FDA approval for NUFYMCO, an interchangeable biosimilar to Lucentis, which is commercialized in the US through a partnership with Zydus Lifesciences. The company operates through licensing agreements with established international pharmaceutical companies for global distribution.

Product and service4 records
1Ranivisio
CategoryBiosimilar Product
Description

Biosimilar to Lucentis (ranibizumab) approved by the European Commission and Swissmedic for treating retinal disorders including age-related macular degeneration (AMD), choroidal neovascularization (CNV), retinal vein occlusion, and diabetic retinopathy. Marketed in Europe and Switzerland through partners including Teva.

2Cimerli
CategoryBiosimilar Product
Description

Biosimilar to Lucentis (ranibizumab) approved by the US FDA as the first interchangeable biosimilar for treating retinal disorders including AMD and diabetic eye diseases. Previously commercialized in the US through partnership with Coherus BioSciences.

3Ongavia
CategoryBiosimilar Product
Description

Biosimilar to Lucentis (ranibizumab) approved by the UK Medicines and Healthcare Regulatory Agency (MHRA) for the treatment of retinal disorders.

4NUFYMCO
CategoryBiosimilar Product
Description

Interchangeable biosimilar to Lucentis (ranibizumab) approved by the US FDA in December 2025 for retinal disorders. Commercialized in the US through partnership with Zydus Lifesciences.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-12-23
Description

Zydus Lifesciences' subsidiary partnered with Bioeq to license and commercialize NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market following FDA approval on December 18, 2025. Bioeq manages development, manufacturing, and registration while Zydus handles commercialization in the US.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polpharma Biologics Group is one of the two parent companies forming the Bioeq joint venture. Together with Formycon AG, they established Bioeq AG to develop, produce, license and commercialize biosimilars globally.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Formycon AG is one of the two parent companies forming the Bioeq joint venture. Together with Polpharma Biologics Group, they established Bioeq AG to develop, produce, license and commercialize biosimilars globally.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership for the commercialization of biosimilar products in Rwanda and Africa. Bio Usawa received approval for BioUcenta, the first biosimilar ranibizumab approved in Africa.

Strategic tierFlagshipTypeChannel Partner/ Reseller/ Distributor
Description

Teva partnered with Bioeq and Formycon to launch Ranivisio, the first Lucentis biosimilar in Europe. Launch began in France with Germany and other countries to follow. Teva has agreements for major European markets and Israel.

6Actor Pharma
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensing agreement for commercialization of biosimilar products in Australia.

gabionline.net
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensing agreement for commercialization of biosimilar products in Latin America.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Licensing agreement for commercialization of biosimilar products in selected European countries.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership for commercialization of Ranibizumab biosimilar in Middle East and Africa regions.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Previous partnership for US commercialization of biosimilar products (November 2019). Status appears historical as current US partnership is with Zydus.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-developer and 50% parent of Bioeq AG. Formycon develops and out-licenses biosimilars including ranibizumab biosimilars (FYB201) and other ophthalmology and immunology assets, making it the closest structural and product comparable to Bioeq.

TypeDirect peer
Description

Alvotech is a pure-play biosimilar developer and manufacturer with multiple approved biosimilars and a pipeline spanning ophthalmology, immunology, and oncology. Comparable to Bioeq as a biosimilar-focused company pursuing global approvals and partner-based commercialization.

TypeBroad incumbent
Description

Amgen operates one of the largest biosimilar franchises (Amgevita, Mvasi, Kanjinti, etc.) and is the originator of several biologic reference products. Comparable as a large established biosimilar player with global commercialization capability, although not specialized solely in ophthalmology.

TypeDirect peer
Description

Celltrion develops, manufactures, and commercializes biosimilars (Remsima, Truxima, etc.) globally, including a ranibizumab biosimilar program. Highly comparable to Bioeq as a biosimilar developer with integrated manufacturing and partner-led commercialization in selected markets.

TypeDirect peer
Description

Former US commercialization partner for Bioeq's ranibizumab biosimilar (Cimerli). Coherus is a US-focused biosimilar and immuno-oncology company commercializing Lucentis and other biosimilars, providing a direct read on US biosimilar commercial dynamics relevant to Bioeq via Zydus.

TypeDirect peer
Description

Samsung Bioepis developed Byooviz, the first FDA-approved Lucentis biosimilar in the US, and is a global biosimilar developer across ophthalmology, immunology, and oncology. Directly competes with Bioeq in the Lucentis biosimilar space and uses a similar licensing-out commercialization model.

TypeDirect peer
Description

50% parent of Bioeq AG and an integrated biosimilar development and manufacturing organization. Operates CDMO and proprietary biosimilar businesses, making it structurally and operationally highly comparable to Bioeq while supplying much of Bioeq's underlying development and manufacturing backbone.

TypeRegional player
Description

Teva is Bioeq's flagship European commercialization partner for Ranivisio and is also a major global biosimilars player (e.g., Truxima partnership) with a leading generics and biosimilars footprint in Europe and Israel. Comparable as the commercial counterpart that drives Bioeq's European revenue.

TypeDirect peer
Description

Biocon Biologics is a major global biosimilar developer and manufacturer with assets across oncology, immunology, and ophthalmology. It pursues a similar out-licensing and partner commercialization strategy and competes in the same regulatory jurisdictions as Bioeq.

TypeBroad incumbent
Description

Pfizer has a broad biosimilars portfolio (Zirabev, Ruxience, Nivestym, etc.) following its Hospira and Mylan integration and competes across ophthalmology and other therapy areas. Comparable as a diversified incumbent with global commercialization reach relevant to biosimilar pricing and access dynamics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bioeq

Biosimilarsbioeq.ch

Bioeq AG is a Swiss biopharmaceutical joint venture (Polpharma Biologics and Formycon) that develops, manufactures, and out-licenses the Ranibizumab biosimilar of Lucentis globally, serving ophthalmology patients with retinal disorders via regional pharmaceutical commercialization partners.

What Bioeq does

Bioeq AG is a Swiss biopharmaceutical joint venture, equally owned by Polpharma Biologics Group and Formycon AG, headquartered in Zug, Switzerland. The company develops, manufactures, licenses, and commercializes biosimilars globally, with a focused portfolio centered on Ranibizumab (FYB201), a monoclonal antibody biosimilar to Roche/Genentech's Lucentis. Ranibizumab targets vascular endothelial growth factor (VEGF) and is indicated for retinal disorders including age-related macular degeneration (AMD), choroidal neovascularization (CNV), retinal vein occlusion, and diabetic retinopathy. The same molecule is marketed under multiple brand names across jurisdictions: Cimerli (US, 2022 FDA approval as the first interchangeable Lucentis biosimilar), Ranivisio (European Commission and Swissmedic, launched commercially in Europe starting November 2025 with Teva), Ongavia (UK MHRA, 2022), NUFYMCO (US, 2025 FDA approval commercialized with Zydus Lifesciences), and BioUcenta (Africa via Bio Usawa).

Bioeq operates an asset-light, B2B licensing and royalty business model. The company itself is small (1-10 employees) and handles development, manufacturing oversight, and registration through its JV parents' capabilities, while out-licensing commercialization rights to established regional pharmaceutical partners in each territory. Key partners include Teva (Europe, Israel), Zydus Lifesciences (US), MS Pharma (Middle East/Africa), Bio Usawa Biotechnology (Rwanda/Africa), Actor Pharma (Australia), Megalabs (Latin America), and Horus Pharma (selected European countries). Pricing is set independently by each partner in its market and is not publicly disclosed by Bioeq. Its customers are therefore pharmaceutical licensees rather than end prescribers or patients, with end-user demand driven by ophthalmologists, hospitals, clinics, and patients seeking affordable alternatives to the high-cost originator Lucentis.

Bioeq firmographics

Firmographics
Name
Bioeq
Legal name
Bioeq AG
Website
https://bioeq.ch
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
Bioeq AG is a Swiss biopharmaceutical joint venture (Polpharma Biologics and Formycon) that develops, manufactures, and out-licenses the Ranibizumab biosimilar of Lucentis globally, serving ophthalmology patients with retinal disorders via regional pharmaceutical commercialization partners.
Ownership category
akta.pro rank

Bioeq industry classification

Industry
Product category
Biosimilars
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAHAJ
Biosimilar Development & Clinical/Regulatory Services (comparability, trials, pharmacovigilance)
SECONDARYHLAAAKAA
Biologic API/Drug Substance Manufacturing Services

Keywords

  • Biosimilar development
  • Biopharmaceutical licensing
  • Monoclonal antibody biosimilars
  • Ophthalmology therapeutics
  • Biologic manufacturing

Where Bioeq is headquartered

Location

Headquarters

HQ city
Zug
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Bioeq business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations

Revenue model

  1. Biosimilar Licensing and Commercialization: Bioeq develops biosimilars and out-licenses them to established pharmaceutical companies for commercialization in specific territories. Partners handle local registration, marketing, and distribution while Bioeq manages development, manufacturing, and supply.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Bioeq product offering

Product offering

Core offering

Bioeq AG is a Swiss biopharmaceutical joint venture that develops, manufactures, and out-licenses biosimilars of biopharmaceutical products globally. Its core offering is a Ranibizumab biosimilar (FYB201) to Lucentis, approved by FDA, EMA, Swissmedic, UK MHRA, and Brazil's ANVISA for retinal disorders including age-related macular degeneration, choroidal neovascularization, retinal vein occlusion, and diabetic retinopathy. The company licenses commercialization rights to established pharmaceutical partners in each territory rather than selling directly, focusing on development, manufacturing, registration, and supply.

Product overview

Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon AG, focused on developing, producing, licensing, and commercializing biosimilars globally. The company's primary product is Ranibizumab, a biosimilar to Lucentis, which is marketed under multiple brand names across different markets: Cimerli (FDA-approved, US), Ranivisio (EC and Swissmedic-approved, Europe/Switzerland), and Ongavia (MHRA-approved, UK). In December 2025, Bioeq received FDA approval for NUFYMCO, an interchangeable biosimilar to Lucentis, which is commercialized in the US through a partnership with Zydus Lifesciences. The company operates through licensing agreements with established international pharmaceutical companies for global distribution.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ranivisio Biosimilar to Lucentis (ranibizumab) approved by the European Commission and Swissmedic for treating retinal disorders including age-related macular degeneration (AMD), choroidal neovascularization (CNV), retinal vein occlusion, and diabetic retinopathy. Marketed in Europe and Switzerland through partners including Teva.
  • Cimerli Biosimilar to Lucentis (ranibizumab) approved by the US FDA as the first interchangeable biosimilar for treating retinal disorders including AMD and diabetic eye diseases. Previously commercialized in the US through partnership with Coherus BioSciences.
  • Ongavia Biosimilar to Lucentis (ranibizumab) approved by the UK Medicines and Healthcare Regulatory Agency (MHRA) for the treatment of retinal disorders.
  • NUFYMCO Interchangeable biosimilar to Lucentis (ranibizumab) approved by the US FDA in December 2025 for retinal disorders. Commercialized in the US through partnership with Zydus Lifesciences.

Quantifiable outcome

  • First Lucentis biosimilar launched in Europe and first interchangeable biosimilar approved by FDA

Companies that use Bioeq

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Bioeq technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Bioeq partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

  • Zydus LifesciencesflagshipChannel Partner/ Reseller/ Distributor · 23 December 2025Zydus Lifesciences' subsidiary partnered with Bioeq to license and commercialize NUFYMCO, an interchangeable biosimilar to Lucentis, in the US market following FDA approval on December 18, 2025. Bioeq manages development, manufacturing, and registration while Zydus handles commercialization in the US.
  • Polpharma Biologics GroupcoreStrategic or Co-development PartnerPolpharma Biologics Group is one of the two parent companies forming the Bioeq joint venture. Together with Formycon AG, they established Bioeq AG to develop, produce, license and commercialize biosimilars globally.
  • Formycon AGcoreStrategic or Co-development PartnerFormycon AG is one of the two parent companies forming the Bioeq joint venture. Together with Polpharma Biologics Group, they established Bioeq AG to develop, produce, license and commercialize biosimilars globally.
  • Bio Usawa Biotechnology Ltd.coreChannel Partner/ Reseller/ DistributorPartnership for the commercialization of biosimilar products in Rwanda and Africa. Bio Usawa received approval for BioUcenta, the first biosimilar ranibizumab approved in Africa.
  • Teva Pharmaceutical IndustriesflagshipChannel Partner/ Reseller/ DistributorTeva partnered with Bioeq and Formycon to launch Ranivisio, the first Lucentis biosimilar in Europe. Launch began in France with Germany and other countries to follow. Teva has agreements for major European markets and Israel.
  • Actor PharmacoreChannel Partner/ Reseller/ DistributorLicensing agreement for commercialization of biosimilar products in Australia.
  • MegalabscoreChannel Partner/ Reseller/ DistributorLicensing agreement for commercialization of biosimilar products in Latin America.
  • Horus PharmacoreChannel Partner/ Reseller/ DistributorLicensing agreement for commercialization of biosimilar products in selected European countries.
  • MS PharmacoreChannel Partner/ Reseller/ DistributorPartnership for commercialization of Ranibizumab biosimilar in Middle East and Africa regions.
  • Coherus BioSciencesminorChannel Partner/ Reseller/ DistributorPrevious partnership for US commercialization of biosimilar products (November 2019). Status appears historical as current US partnership is with Zydus.

Scale indicators2 records

Recent moves7 records

Expansion highlights6 records

Bioeq competitors and assessment

Company assessment

Direct peers

  • Formycon AG: Co-developer and 50% parent of Bioeq AG. Formycon develops and out-licenses biosimilars including ranibizumab biosimilars (FYB201) and other ophthalmology and immunology assets, making it the closest structural and product comparable to Bioeq.
  • Alvotech: Alvotech is a pure-play biosimilar developer and manufacturer with multiple approved biosimilars and a pipeline spanning ophthalmology, immunology, and oncology. Comparable to Bioeq as a biosimilar-focused company pursuing global approvals and partner-based commercialization.
  • Celltrion: Celltrion develops, manufactures, and commercializes biosimilars (Remsima, Truxima, etc.) globally, including a ranibizumab biosimilar program. Highly comparable to Bioeq as a biosimilar developer with integrated manufacturing and partner-led commercialization in selected markets.
  • Coherus BioSciences: Former US commercialization partner for Bioeq's ranibizumab biosimilar (Cimerli). Coherus is a US-focused biosimilar and immuno-oncology company commercializing Lucentis and other biosimilars, providing a direct read on US biosimilar commercial dynamics relevant to Bioeq via Zydus.
  • Samsung Bioepis: Samsung Bioepis developed Byooviz, the first FDA-approved Lucentis biosimilar in the US, and is a global biosimilar developer across ophthalmology, immunology, and oncology. Directly competes with Bioeq in the Lucentis biosimilar space and uses a similar licensing-out commercialization model.
  • Polpharma Biologics Group: 50% parent of Bioeq AG and an integrated biosimilar development and manufacturing organization. Operates CDMO and proprietary biosimilar businesses, making it structurally and operationally highly comparable to Bioeq while supplying much of Bioeq's underlying development and manufacturing backbone.
  • Biocon Biologics: Biocon Biologics is a major global biosimilar developer and manufacturer with assets across oncology, immunology, and ophthalmology. It pursues a similar out-licensing and partner commercialization strategy and competes in the same regulatory jurisdictions as Bioeq.

Broad incumbents

  • Amgen (Biosimilars): Amgen operates one of the largest biosimilar franchises (Amgevita, Mvasi, Kanjinti, etc.) and is the originator of several biologic reference products. Comparable as a large established biosimilar player with global commercialization capability, although not specialized solely in ophthalmology.
  • Pfizer (Biosimilars): Pfizer has a broad biosimilars portfolio (Zirabev, Ruxience, Nivestym, etc.) following its Hospira and Mylan integration and competes across ophthalmology and other therapy areas. Comparable as a diversified incumbent with global commercialization reach relevant to biosimilar pricing and access dynamics.

Regional players

  • Teva Pharmaceutical Industries: Teva is Bioeq's flagship European commercialization partner for Ranivisio and is also a major global biosimilars player (e.g., Truxima partnership) with a leading generics and biosimilars footprint in Europe and Israel. Comparable as the commercial counterpart that drives Bioeq's European revenue.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Bioeq financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bioeq leadership team

Management profile

Number of profiles

Profiles7 records

Bioeq funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bioeq M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bioeq

What does Bioeq do?

Bioeq AG is a Swiss biopharmaceutical joint venture that develops, manufactures, and out-licenses biosimilars of biopharmaceutical products globally. Its core offering is a Ranibizumab biosimilar (FYB201) to Lucentis, approved by FDA, EMA, Swissmedic, UK MHRA, and Brazil's ANVISA for retinal disorders including age-related macular degeneration, choroidal neovascularization, retinal vein occlusion, and diabetic retinopathy. The company licenses commercialization rights to established pharmaceutical partners in each territory rather than selling directly, focusing on development, manufacturing, registration, and supply.

Is Bioeq a public or private company?

Bioeq is a private company. It is classified as corporate owned and is currently operating.

When was Bioeq founded?

Bioeq was founded in -1. It employs 11 to 50 people.

Where is Bioeq based?

Bioeq is headquartered in Zug, Switzerland, in the Europe region.

How does Bioeq make money?

One revenue line is on record: biosimilar Licensing and Commercialization.

Who are Bioeq's main competitors?

Direct peers on record are Formycon AG, Alvotech, Celltrion, Coherus BioSciences, Samsung Bioepis, Polpharma Biologics Group and Biocon Biologics. Broad incumbents are Amgen (Biosimilars) and Pfizer (Biosimilars). Teva Pharmaceutical Industries is listed as a regional player.

Does Bioeq have an API?

No public API is recorded for Bioeq.

What industry is Bioeq in?

Bioeq's product category is Biosimilars. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireLUCENTIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and JapanResearchAndMarkets.com published a market analysis report on LUCENTIS sales forecasts covering 2026-2034 across the US, EU4, UK, and Japan. In December 2025, the FDA approved Nufymco, an interchangeable biosimilar developed by Formycon and Bioeq, as a competitor to LUCENTIS for retinal disorders. The report details that LUCENTIS, developed by Genentech (Roche), reached peak global sales of $1.8 billion in 2019 but has faced revenue declines due to biosimilar competition.Ophthalmology TimesBrazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)Brazil's ANVISA granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis, developed by Bioeq AG. Formycon announced a commercialisation partnership with Biomm, with a Brazilian launch expected in Q4 2025. Further approvals and launches across Latin America are planned through early 2027.BusinessLineWhy these 4 healthcare stocks will remain in focus on WednesdayZydus Lifesciences' subsidiary partnered with Swiss company Bioeq AG to license, supply and commercialize the FDA-approved biosimilar NUFYMCO in the US market. Biocon out-licensed its Semaglutide diabetes drug to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia. Emcure Pharmaceuticals received a No Action Indicated classification from the USFDA following an inspection of its manufacturing facility in Kadu, Surendranagar.Pharmaceutical TechnologyZydus and Bioeq partner for commercialisation of Nufymco in USZydus Lifesciences Global FZE, a subsidiary of Zydus, has partnered with Bioeq for the US commercialization of Nufymco, an interchangeable biosimilar of Lucentis (Ranibizumab), following FDA approval of the Biologics License Application. Under the agreement, Bioeq will handle development, manufacturing, registration, and supply while Zydus will focus on commercialization across the US market. The partnership expands Zydus' biosimilar portfolio and leverages combined expertise to improve patient access to affordable ophthalmology treatments.PR NewswireZydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®Bioeq AG and Zydus Lifesciences Limited announced a strategic partnership granting Zydus the U.S. commercialization rights for NUFYMCO®, an interchangeable biosimilar to Lucentis®. This collaboration follows the recent approval of NUFYMCO's Biologics License Application by the USFDA on December 18, 2025. Under the agreement, Bioeq will handle development and supply while Zydus manages U.S. marketing and distribution.ScanXZydus Partners with Bioeq for US Biosimilar Rights to NUFYMCOZydus Lifesciences has partnered with Swiss biopharmaceutical company Bioeq AG to commercialize NUFYMCO, an interchangeable biosimilar to Lucentis (Ranibizumab), in the US market. Under the agreement, Zydus will handle commercialization while Bioeq manages development, manufacturing, and supply. The biosimilar received FDA approval on December 18, 2025, and targets a market opportunity estimated at $210 million.India InfolineZydus Lifesciences Partners Bioeq to Commercialise Ranibizumab Biosimilar in USZydus Lifesciences Limited has entered a strategic partnership with Bioeq AG to commercialise NUFYMCO, an interchangeable biosimilar to Lucentis, in the United States. The US Food and Drug Administration approved the Biologics License Application for NUFYMCO on December 18, 2025, enabling its market launch. Under the agreement, Zydus handles US commercialisation while Bioeq manages development, manufacturing, and supply.GlobeNewswireBio Usawa Biotechnology and Bioeq AG Partner to Create Widespread Access to Vision-Saving Medicine Across Sub-Saharan AfricaBio Usawa and Bioeq AG announced a partnership to bring ranibizumab biosimilar BioUcenta to Sub-Saharan Africa, with Bio Usawa granted exclusive rights. The medicine treats diabetic macular edema and wet AMD, and Africa's diabetes cases are projected to double by 2050.GlobeNewswireBio Usawa Biotechnology and Bioeq AG Partner to Create Widespread Access to Vision-Saving Medicine Across Sub-Saharan AfricaBio Usawa Biotechnology and Bioeq AG announced a partnership to bring ranibizumab biosimilar BioUcenta to Sub-Saharan Africa. The biosimilar, approved in Europe and the US, will be registered and distributed by Bio Usawa to treat diabetic macular edema and wet AMD. The deal aims to address the region's diabetes crisis, with over 24 million Africans living with diabetes in 2024.